slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
231,421-231,480 of 319,975
02
Includes detailed footnotes regarding funding assumptions and timing.Houlihan Lokey | Investment Banking Pitch Book | 8 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Problem1 hit
03
Includes detailed footnotes regarding assumptions and specific investor commitments.Houlihan Lokey | Investment Banking Pitch Book | 8 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Problem1 hit
04
Includes a red dashed box highlighting the negative cash flow trend in the final weeks.Houlihan Lokey | Investment Banking Pitch Book | 8 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Problem1 hit
05
Includes footnotes regarding specific investor conditions and disclaimers about the nature of the funding.Houlihan Lokey | Investment Banking Pitch Book | 8 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Problem1 hit
06
Houlihan Lokey | Investment Banking Pitch Book | 8 slidesHoulihan Lokey | Investment Banking Pitch Book | 8 slides · Houlihan Lokey
Consulting deck Investment bank 1 hit
07
Houlihan Lokey | Investment Banking Pitch Book | 8 slidesHoulihan Lokey | Investment Banking Pitch Book | 8 slides · Houlihan Lokey
Consulting deck Investment bank 1 hit
08
Houlihan Lokey | Investment Banking Pitch Book | 8 slidesHoulihan Lokey | Investment Banking Pitch Book | 8 slides · Houlihan Lokey
Consulting deck Investment bank 1 hit
01
Matson | Results Presentation Deck | 18 slidesMatson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Setup1 hit
02
Matson | Results Presentation Deck | 18 slidesMatson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Setup1 hit
03
Matson | Results Presentation Deck | 18 slidesMatson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Setup1 hit
04
Matson | Results Presentation Deck | 18 slidesMatson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · So What Cascade1 hit
05
Includes a dual-axis line chart for historical trends and a table for future projections.Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · So What Cascade1 hit
06
The chart compares 2023 quarterly volumes against Q1 2024 volume.Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · So What Cascade1 hit
07
Matson | Results Presentation Deck | 18 slidesMatson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · So What Cascade1 hit
08
The chart shows quarterly container volume (FEU) for 2023 and Q1 2024.Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · So What Cascade1 hit
09
The chart shows quarterly container volume comparisons between 2023 and 2024, with a specific note on sailing frequency impact.Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · So What Cascade1 hit
10
Matson | Results Presentation Deck | 18 slidesMatson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · So What Cascade1 hit
11
The chart shows quarterly operating income for 2023 (dark blue) and Q1 2024 (orange).Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · So What Cascade1 hit
12
Includes GAAP EPS and EBITDA reconciliation metrics.Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · EvidenceLoop · Pareto Focus1 hit
13
The chart shows a bridge from starting cash flow to net change in cash.Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · EvidenceLoop · Pareto Focus1 hit
14
Includes specific footnotes regarding debt calculation and post-period tax refund events.Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · EvidenceLoop · Pareto Focus1 hit
15
Matson | Results Presentation Deck | 18 slidesMatson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · 2024 OutlookLoop · Cost Of Inaction1 hit
16
Matson | Results Presentation Deck | 18 slidesMatson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Valuation Table1 hit
17
Matson | Results Presentation Deck | 18 slidesMatson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations 1 hit
18
Includes a detailed footnote explaining the definition and limitations of EBITDA as a non-GAAP measure.Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations 1 hit
01
Nuvalent | Investor Presentation Deck | 42 slidesNuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
02
Nuvalent | Investor Presentation Deck | 42 slidesNuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
03
The slide uses a 2x2 grid layout to present key company metrics.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Loop · Golden Circle1 hit
04
Nuvalent | Investor Presentation Deck | 42 slidesNuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
05
The slide uses a timeline-based structure to demonstrate historical progress and future financial stability.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
06
The slide uses a timeline visual to connect high-level goals with specific 2024 milestones.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
07
The slide uses a split layout with a left-hand sidebar for board/advisors and a right-hand grid for the leadership team.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
08
The slide uses a standard pharmaceutical pipeline visualization format.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
09
The slide uses a structured table to contrast two distinct patient populations (ALK+ vs ROS1+) and their respective treatment challenges.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Uses a case study (Osimertinib) to validate the proposed strategy for ALK/ROS1 targets.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
11
The chart uses a bar-horizontal format to compare sales figures for specific drugs (Alectinib, Crizotinib) against a group of 'Other' TKIs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Market Size1 hit
12
The slide uses a sidebar 'AT A GLANCE' to summarize key clinical development parameters.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
13
The slide uses a timeline-based framework to map treatment lines (1L, 2L, 3L+) against clinical challenges.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
14
The slide uses a matrix-style comparison to highlight the superior coverage of NVL-655 compared to 1st, 2nd, and 3rd generation inhibitors.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
15
The slide uses a split-screen layout to contrast in vitro IC50 data with in vivo tumor regression data.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
16
The slide uses two distinct chart types (bar and scatter) to demonstrate pharmacological advantages.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
Includes detailed patient enrollment breakdown by dose cohort and trial phase.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
18
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
19
Data cut-off: 8 Aug 2023. Includes detailed breakdown of response by mutation type and prior treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
20
Clinical trial data (ALKOVE-1) showing efficacy of NVL-655 in NSCLC patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
21
The chart is a classic swimmer plot used in oncology clinical trials to visualize time-to-event data.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
22
Includes two patient case studies with MRI scans showing tumor reduction.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
23
Data cut-off: 8 Aug 2023. N=93 patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
24
The chart shows NVL-655 pharmacokinetics across five dose cohorts, highlighting that the 150mg dose maintains levels above efficacy thresholds for various ALK mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and define the specific clinical opportunity for each.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
26
Includes a table detailing patient cohorts and study objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
27
The slide uses a sidebar 'AT A GLANCE' to summarize key clinical and regulatory status.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
28
Uses a timeline-based framework to contrast current treatment standards with unmet clinical needs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
29
The slide uses a visual comparison matrix to highlight the therapeutic advantages of Zidesamtinib.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
30
The slide uses three distinct chart types to demonstrate competitive superiority in potency, CNS penetration, and selectivity.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
31
The slide provides a detailed breakdown of patient enrollment across different dose cohorts (25mg to 125mg QD) for the ARROS-1 trial.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
32
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
33
Includes a waterfall plot and a summary table of best responses.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
34
Includes clinical trial data for Zidesamtinib (NVL-520) in ARROS-1 Phase 1 study.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
35
Data from ARROS-1 Phase 1 trial.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit